Market Overview:
The global pigmented villonodular synovitis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of PVNS, rising awareness about PVNS and its treatment options, and the launch of novel drugs for the treatment of PVNS. Based on type, the global pigmented villonodular synovitis drug market is segmented into cabiralizumab, emactuzumab, mcs-110, nilotinib, and others. Cabiralizumab held a major share of the global pigmented villonodular synovitis drug market in 2017 owing to its high efficacy and safety profile. The cabiralizumab segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, hospital held a major share of the global pigmented villonodular synovitis drug market in 2017 owing to increased use of cabiralizumab for treating PVNS in hospitals across regions.
Product Definition:
Pigmented Villonodular Synovitis Drug is a drug that is used to treat Pigmented Villonodular Synovitis.
Cabiralizumab:
Cabiralizumab is a humanized monoclonal antibody designed for the treatment of patients with advanced melanoma. The drug was approved by the FDA in March 2017 and has been assigned an orphan drug status by the European Commission.
Emactuzumab:
Emactuzumab is a humanized monoclonal antibody designed for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and pigment villonodular synovitis (PVNS). The drug was approved by the U.S.
Application Insights:
The others segment held the largest market share in 2017 and is anticipated to grow at a lucrative rate over the forecast period. The growth can be attributed to increasing product approvals for other indications, such as rheumatoid arthritis and Crohn¢â‚¬â„¢s disease. For instance, in September 2017, Pfizer Inc. announced that it would discontinue development of cabiralizumab for psoriasis (phase III) due to lack of commercial interest from patients and health care providers regarding this treatment option. However, hospital-based pigmented villonodular synovitis treatments are expected to witness significant growth owing to their high therapeutic value as compared with other applications.
Based on application type, the global market has been further segmented into hospital-based PVsNS therapy; clinic-based PVNS therapy; others;.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives and increasing R&D activities are some of the major factors contributing to its growth. For instance, in September 2016, Pfizer Inc. received approval from the U.S FDA for Zolgensma’s branded as Zepatier (nilotinib) for sale in U.S.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to rising healthcare expenditure and improving economic conditions especially in developing countries such as India.
Growth Factors:
- Increasing incidence of Pigmented Villonodular Synovitis (PVNS)
- Rising awareness about PVNS and its treatment options
- Growing demand for better and more effective treatments for PVNS
- Availability of novel, targeted therapies for PVNS
- increasing investment in research and development of new drugs to treat PVNS
Scope Of The Report
Report Attributes
Report Details
Report Title
Pigmented Villonodular Synovitis Drug Market Research Report
By Type
Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others
By Application
Hospital, Clinic, Others
By Companies
Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, Plexxikon Inc, Bristol-Myers Squibb Co
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Pigmented Villonodular Synovitis Drug Market Report Segments:
The global Pigmented Villonodular Synovitis Drug market is segmented on the basis of:
Types
Cabiralizumab, Emactuzumab, Mcs-110, Nilotinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb Co
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Plexxikon Inc
- Bristol-Myers Squibb Co
Highlights of The Pigmented Villonodular Synovitis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cabiralizumab
- Emactuzumab
- Mcs-110
- Nilotinib
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pigmented Villonodular Synovitis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pigmented villonodular synovitis (PVNS) is a rare condition that causes inflammation and pain in the muscles and tendons around the joints. PVNS can be caused by a number of different things, including infection, autoimmune disease, or cancer. Treatment typically involves using medications to reduce inflammation and pain.
Some of the major players in the pigmented villonodular synovitis drug market are Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, Plexxikon Inc, Bristol-Myers Squibb Co.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pigmented Villonodular Synovitis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pigmented Villonodular Synovitis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pigmented Villonodular Synovitis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pigmented Villonodular Synovitis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pigmented Villonodular Synovitis Drug Market Size & Forecast, 2020-2028
4.5.1 Pigmented Villonodular Synovitis Drug Market Size and Y-o-Y Growth
4.5.2 Pigmented Villonodular Synovitis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cabiralizumab
5.2.2 Emactuzumab
5.2.3 Mcs-110
5.2.4 Nilotinib
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pigmented Villonodular Synovitis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pigmented Villonodular Synovitis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cabiralizumab
9.6.2 Emactuzumab
9.6.3 Mcs-110
9.6.4 Nilotinib
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cabiralizumab
10.6.2 Emactuzumab
10.6.3 Mcs-110
10.6.4 Nilotinib
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cabiralizumab
11.6.2 Emactuzumab
11.6.3 Mcs-110
11.6.4 Nilotinib
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cabiralizumab
12.6.2 Emactuzumab
12.6.3 Mcs-110
12.6.4 Nilotinib
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cabiralizumab
13.6.2 Emactuzumab
13.6.3 Mcs-110
13.6.4 Nilotinib
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pigmented Villonodular Synovitis Drug Market: Competitive Dashboard
14.2 Global Pigmented Villonodular Synovitis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb Co
14.3.2 F. Hoffmann-La Roche Ltd
14.3.3 Novartis AG
14.3.4 Plexxikon Inc
14.3.5 Bristol-Myers Squibb Co
